- Home
- CDE vs EXEL Comparison
CDE vs EXEL Comparison
Compare CDE & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CDE | EXEL |
|---|---|---|
| Founded | 1928 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.4B |
| IPO Year | 1994 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CDE | EXEL |
|---|---|---|
| Price | $19.42 | $44.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | $22.40 | ★ $46.45 |
| AVG Volume (30 Days) | ★ 27.5M | 2.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 533.33 | 57.95 |
| EPS | 0.95 | ★ 2.78 |
| Revenue | ★ $709,598,000.00 | $452,477,000.00 |
| Revenue This Year | $170.80 | $13.61 |
| Revenue Next Year | $27.10 | $13.13 |
| P/E Ratio | $20.78 | ★ $15.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.21 | $33.76 |
| 52 Week High | $27.77 | $48.74 |
Technical Indicators
Market Signals| Indicator | CDE | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.49 | 55.27 |
| Support Level | $19.08 | $40.53 |
| Resistance Level | $19.73 | $45.88 |
| Average True Range (ATR) | 1.16 | 1.10 |
| MACD | 0.32 | 0.16 |
| Stochastic Oscillator | 62.39 | 62.47 |
Price Performance
Historical ComparisonAbout CDE Coeur Mining Inc.
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada, and Mexico generating maximum revenue from United States.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.